Views & Analysis | Perspectives on pharma industry issues

Digital

Abstract AI concept, turquoise hexagonals on dark background

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

R&D

A certificate of analysis should be evidence, not a sales do...

Regulators weighing peptide bulk substances can ask whether today's documentation rules fit the risks of this supply chain.

R&D

From phase 1 to phase 3: Scaling radiopharmaceutical trials

Success in radiopharmaceutical development depends on creating and maintaining an integrated, scalable system.

Patients

pharmaphorum podcast Episode 285, Donna Cryer, CryerHealth, LLC

Patients not just at the table, but creating their own: In c...

Donna Cryer, founding partner and Chief Patient Officer of CryerHealth, LLC discusses why is patient inclusion is not the same as patient leadership.

R&D

Gravity is an experimental variable pharma has rarely been a...

Microgravity should not be a destination for pharmaceutical R&D, but another experimental environment.

Articles

Pharma gets social: social mobile app helps Pfizer engage co...

This month in 'Pharma gets social', Daniel Ghinn takes a look at Pfizer’s mobile health app for those with overactive bladders. Social mobile app connects Pfizer with the right patients in the right place! There are no other emerging digital channels that capture the…

Articles

Media perspectives: Ed Silverman

Kicking off the start of a new series where we speak with key media figures in pharma and healthcare, pharmaphorum caught up with Ed Silverman, the Editor of Pharmalot. There’s never a dull moment in pharma, with every day bringing new breaking stories covering everything from updates on development and…

Articles

The ‘supply chain’ patient is sick: is there a cure for the ...

In the first of two parts, Hedley Rees looks at the problems with the pharmaceutical supply chain and questions whether they can be resolved. The Pharmaceutical supply chain has never been in such turmoil and under such attack from governments and regulators globally. The evidence is...

Sales & Marketing

Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Digital

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

Digital

Sponsored

Antiviral development in the age of AI: From pre-IND to earl...

hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.